| Literature DB >> 33728824 |
Caroline Huart1,2, Carl M Philpott3,4, Aytug Altundag5, Alexander W Fjaeldstad6,7, Johannes Frasnelli8, Simon Gane9,10, Julien W Hsieh11, Eric H Holbrook12, Iordanis Konstantinidis13, Basile N Landis11, Alberto Macchi14, Christian A Mueller15, Simona Negoias16, Jayant M Pinto17, Sophia C Poletti18, Vijay R Ramakrishnan19, Philippe Rombaux1,2, Jan Vodicka20, Antje Welge-Lüessen16, Katherine L Whitcroft10,21, Thomas Hummel22.
Abstract
The frequent association between coronavirus disease 2019 (COVID-19) and olfactory dysfunction is creating an unprecedented demand for a treatment of the olfactory loss. Systemic corticosteroids have been considered as a therapeutic option. However, based on current literature, we call for caution using these treatments in early COVID-19-related olfactory dysfunction because: (1) evidence supporting their usefulness is weak; (2) the rate of spontaneous recovery of COVID-19-related olfactory dysfunction is high; and (3) corticosteroids have well-known potential adverse effects. We encourage randomized placebo-controlled trials investigating the efficacy of systemic steroids in this indication and strongly emphasize to initially consider smell training, which is supported by a robust evidence base and has no known side effects.Entities:
Keywords: COVID-19; SARS-CoV-2; corticosteroids; olfaction disorder; smell
Year: 2021 PMID： 33728824 DOI： 10.1002/alr.22788
Source DB: PubMed Journal: Int Forum Allergy Rhinol ISSN： 2042-6976 Impact factor: 3.858